Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-11-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-2083PMID 27852699PMCID PMC5440207
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of ROR1 has prognostic significance in triple negative breast cancer

  2016influential reference
• Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.

  2016cited by this paper
• ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1

  2016influential reference
• Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

  2015cited by this paper
• Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.

  2015cited by this paper
• Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

  2015cited by this paper
• Receptor tyrosine kinase expression of circulating tumor cells in small cell lung cancer

  2015cited by this paper
• Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations

  2015cited by this paper
• Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma

  2015influential reference
• Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma.

  2015influential reference
• The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies

  2015cited by this paper
• Remote control of therapeutic T cells through a small molecule–gated chimeric receptor

  2015cited by this paper
• ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

  2014cited by this paper
• Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells

  2014cited by this paper
• ROR1 expression correlated with poor clinical outcome in human ovarian cancer

  2014cited by this paper
• Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy

  2014cited by this paper
• Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

  2013cited by this paper
• Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells

  2013cited by this paper
• Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma

  2013cited by this paper
• Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

  2013cited by this paper
• Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

  2013cited by this paper
• The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells

  2013cited by this paper
• Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

  2013cited by this paper
• ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy

  2012cited by this paper
• Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies

  2012influential reference
• ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth

  2012cited by this paper
• Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

  2012cited by this paper
• The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.

  2012influential reference
• Targeting malignant B cells with an immunotoxin against ROR1

  2012cited by this paper
• NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.

  2012influential reference
• Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.

  2012cited by this paper
• Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells

  2012cited by this paper
• Post‐translational modifications regulate signalling by Ror1

  2011cited by this paper
• The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

  2010cited by this paper
• Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

  2010cited by this paper
• New flow cytometric assays for monitoring cell-mediated cytotoxicity

  2010cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there.

  2009cited by this paper
• Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy

  2008cited by this paper
• Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

  2008cited by this paper
• Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette

  2008cited by this paper
• Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

  2008influential reference
• Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking

  2008cited by this paper
• Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

  2007cited by this paper
• Retinoic acid imprints gut-homing specificity on T cells.

  2004cited by this paper
• Redirecting Migration of T Cells to Chemokine Secreted from Tumors by Genetic Modification with CXCR2

  2002cited by this paper
• Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development

  2001cited by this paper
• Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells

  2001cited by this paper
• Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia

  2001cited by this paper
• Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains.

  1996cited by this paper

• ROR1 protein: a pseudokinase at the crossroads of cancer progression and therapy

  2026influential citation
• Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer

  2026cites this paper
• Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer

  2026cites this paper
• Targeting WTAP/ROR1/WNT5A-Mediated Crosstalk Between Glioma Stem Cells and Macrophages to Normalize Tumor Vasculature and Enhance Chemotherapy.

  2026cites this paper
• Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.

  2025cites this paper
• Discovery of a potent ROR1 inhibitor using μs-scale MD simulations, wt-metadynamics, and absolute binding free energy calculations

  2025cites this paper
• Development of Novel Peptide-Based 68Ga-Labeled Radiotracers for Detecting ROR1 Expression in Tumors.

  2025cites this paper
• CAR-T for Lung Cancers: Challenges and Innovations.

  2025cites this paper
• Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

  2025cites this paper
• Unveiling CTRB2, RSPO3, KLOTB, and ROR1 as obesity-pancreatic disease association proteins: a comprehensive Mendelian randomization study

  2025cites this paper
• ROR1 as an Immunotherapeutic Target for Inducing Antitumor Helper T Cell Responses Against Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Upregulated Claudin-18.2 Is a Poor Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy.

  2025cites this paper
• Development of nanobody-based PROTAC (NbTAC) for ROR1 degradation by RNF149.

  2025cites this paper
• Comprehensive advances in HER2-positive and HER2-negative breast cancer: unveiling molecular mechanisms and exploring cutting-edge targeted therapies for enhanced patient outcomes

  2025cites this paper
• Uncovering a Novel Role of ROR1 in the Epigenetic Regulation of Tumor Suppressor Gene CREB3L1 in Triple-Negative Breast Cancer Cells

  2025cites this paper
• Structure-directing optimization of N-(2,3-dihydrobenzo[b] [1,4]dioxin-6-yl)benzamide derivatives as selective receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitors for cancer therapy.

  2025cites this paper
• Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells

  2025cites this paper
• The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models

  2025cites this paper
• Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors

  2025cites this paper
• Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma

  2025cites this paper
• Single‐Cell Analysis Clarifies Pathological Heterogeneity in Tenosynovial Giant Cell Tumor and Identifies Biomarkers for Predicting Disease Recurrence

  2025cites this paper
• ZP4: A Novel Target for CAR T Cell Therapy in Triple Negative Breast Cancer.

  2025cites this paper
• Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer

  2025cites this paper
• ROR1 CAR-T cells and ferroptosis inducers orchestrate tumor ferroptosis via PC-PUFA2

  2025influential citation
• A novel fully human anti-ROR1 antibody PBA-0405 optimized for ADCC, induces potent anti-tumor activity against both solid and hematological malignancies

  2025cites this paper
• An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target

  2025cites this paper
• Inducing ferroptosis to improve cancer therapy: a promising tool for enhancing immunotherapy

  2025cites this paper
• Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

  2024cites this paper
• A Prodrug Nanodevice Co-delivering Docetaxel and ROR1 siRNA for Enhanced Triple Negative Breast Cancer Therapy.

  2024cites this paper
• Targeting ROR2 homooligomerization disrupts ROR2-dependent signaling and suppresses stem-like cell properties of human breast adenocarcinoma

  2024cites this paper
• CHEMOTHERAPY, IMMUNOTHERAPY, AND TARGETED THERAPY FOR OSTEOSARCOMA: RECENT ADVANCEMENTS.

  2024cites this paper
• Therapeutic advances in the targeting of ROR1 in hematological cancers

  2024cites this paper
• Highly specific detection of ROR1 cancer biomarker with bipolar electrochemiluminescence

  2024cites this paper
• Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types

  2024cites this paper
• Protein biomarkers for subtyping breast cancer and implications for future research: a 2024 update

  2024cites this paper
• Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies

  2024cites this paper
• ROR1 facilitates glioblastoma growth via stabilizing GRB2 to promote c-Fos expression in glioma stem cells

  2024cites this paper
• Embryonic macrophages support endocrine commitment during human pancreatic differentiation.

  2024cites this paper
• Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation

  2024cites this paper
• Novel humanized monoclonal antibodies against ROR1 for cancer therapy

  2024cites this paper
• T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting

  2024cites this paper
• Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein

  2024cites this paper
• Development of Peptide Paratope Mimics Derived from the Anti-ROR1 Antibody and Long-Acting Peptide-Drug Conjugates for Targeted Cancer Therapy.

  2024cites this paper
• Discovery of Novel Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors for Cancer Treatment.

  2024cites this paper
• Exosomal ROR1 in peritoneal fluid identifies peritoneal disseminated PDAC and is associated with poor survival

  2024cites this paper
• Heterogeneous Profile of ROR1 Protein Expression across Tumor Types

  2024influential citation
• Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells.

  2024cites this paper
• A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

  2024cites this paper
• Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engager

  2024cites this paper
• Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts

  2024cites this paper
• How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia

  2024cites this paper
• The oncogenic roles and clinical implications of YAP/TAZ in breast cancer

  2023cites this paper
• Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential

  2023cites this paper
• Current status and future challenges of CAR-T cell therapy for osteosarcoma

  2023cites this paper
• Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer

  2023cites this paper
• De Novo Discovery of Cysteine Frameworks for Developing Multicyclic Peptide Libraries for Ligand Discovery.

  2023cites this paper
• Exploration of macrocyclic peptide binders to the extracellular CRD domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR1).

  2023cites this paper
• CAR-T cell therapy for hematological malignancies: History, status and promise

  2023cites this paper
• Recent advances in genomics and therapeutics in mantle cell lymphoma.

  2023cites this paper
• Detection of receptor tyrosine kinase-orphan receptor-2 using an electrochemical immunosensor modified with electrospun nanofibers comprising polyvinylpyrrolidone, soy, and gold nanoparticles

  2023cites this paper
• ROR1-AS1 might promote in vivo and in vitro proliferation and invasion of cholangiocarcinoma cells

  2023cites this paper
• Identification and validation of a small molecule targeting ROR1 for the treatment of triple negative breast cancer

  2023cites this paper
• Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments

  2023cites this paper
• Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

  2023cites this paper
• ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype

  2023cites this paper
• Use of a hybrid intelligence decision tree to identify mature B‐cell neoplasms

  2023cites this paper
• Macrophages heterogeneity and significance during human fetal pancreatic development

  2023cites this paper
• Evaluation of the prognostic significance of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in lung carcinoma and its relation to lymphangiogenesis and epithelial mesenchymal transition.

  2023cites this paper
• Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives

  2023cites this paper
• ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity

  2023cites this paper
• The Notch signaling pathway: a potential target for cancer immunotherapy

  2023cites this paper
• Multi-targeted immunotherapeutics to treat B cell malignancies.

  2023cites this paper
• The signaling pathways activated by ROR1 in cancer.

  2023cites this paper
• A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells

  2023cites this paper
• Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer.

  2023cites this paper
• Anti-ROR1 CAR-T cells: Architecture and performance

  2023influential citation
• Transcriptomic Biomarker Signatures for Discrimination of Oral Cancer Surgical Margins

  2022cites this paper
• Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.

  2022cites this paper
• CAR‐T cell therapy for lung cancer: Potential and perspective

  2022cites this paper
• CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application

  2022cites this paper
• EMT alterations in the solute carrier landscape uncover SLC22A10/A15 imposed vulnerabilities in pancreatic cancer

  2022cites this paper
• Crystal structure of the kringle domain of human receptor tyrosine kinase-like orphan receptor 1 (hROR1)

  2022cites this paper
• Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity

  2022cites this paper
• ROR1: an orphan becomes apparent

  2022cites this paper
• Chondroitin Sulfates Control Invasiveness of the Basal-Like Breast Cancer Cell Line MDA-MB-231 Through ROR1

  2022cites this paper
• Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer

  2022cites this paper
• Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC

  2022cites this paper
• ROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancer

  2022cites this paper
• Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities

  2022cites this paper
• ROR1-targeting switchable CAR-T cells for cancer therapy

  2022cites this paper
• Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies

  2022cites this paper
• CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19.

  2022cites this paper
• Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF‐1α regulator

  2021cites this paper
• CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma

  2021cites this paper
• The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention

  2021influential citation
• Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.

  2021cites this paper
• Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.

  2021cites this paper
• Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.

  2021cites this paper
• Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1

  2021influential citation
• A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy

  2021influential citation